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Phosphodiesterases 4 (PDE4) act as proinflammatory enzymes via degradation of 
cAMP, while PDE4 inhibitors play an anti-inflammatory role in vitro and in vivo. In 
particular, apremilast has been recently approved for the treatment of psoriasis and 
psoriatic arthritis. However, little is known on the expression pattern of PDE4 in 
psoriasis. We report that PDE4B and PDE4D mRNA are overexpressed in peripheral 
blood mononuclear cells (PBMC) from psoriasis, as compared to normal controls, while 
apremilast reduces PBMC production of a number of pro-inflammatory cytokines and 
increases the levels of anti-inflammatory mediators. PDE4 expression is up-regulated in 
psoriatic dermis, as compared to normal skin, with particular regard to fibroblasts. This 
is confirmed in vitro, where both dermal fibroblasts (DF) and, to a greater extent, 
myofibroblasts (DM) express all PDE4 isoforms at the mRNA and protein level. 
Because PDE4 interacts with the nerve growth factor receptor CD271 in lung 
fibroblasts, we evaluated the relationship and function of PDE4 and CD271 in normal 
human skin fibroblasts. All PDE4 isoforms co-immunoprecipitate with CD271 in DM, 
while apremilast inhibits apoptosis induced by β-amyloid, a CD271 ligand, in DM. 
Furthermore, apremilast significantly reduces NGF- and TGFb1-induced fibroblasts 
migration, and inhibits DF differentiation into DM mediated by NGF or TGFb1. Finally, in 
DM, apremilast significantly reduces cAMP degradation induced by treatment with β-
amyloid. Taken together, these results indicate that PDE4 play an important role in 
psoriasis. In addition, the study reveals that the complex PDE4/CD271 could be 
important in modulating fibroblasts functions. 
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ABBREVIATIONS 
AD = atopic dermatitis 
ANOVA = analysis of variance 
BSA = body surface area 
cAMP = cyclic adenosine monophosphate 
DF = dermal fibroblasts 
DLE = discoid lupus erythematosus 
DM = dermal myofibroblasts 
DMSO = dimethyl sulfoxide 
ELISA = enzyme-linked immunosorbent assay 
IgM = immunoglobulin M 
IHC = immunohistochemistry 
IPF = idiopathic pulmonary fibrosis 
LPS = lipopolysaccharide 
MCP = monocyte chemotactic protein 
MIP = macrophage inflammatory protein 
NGF = nerve growth factor 
NR = not reported 
PASI = Psoriasis Area and Severity Index 
PBMC = peripheral blood mononuclear cells 
PDE = phosphodiesterase 
PI = propidium iodide 
PsA = psoriatic arthritis 
RA = rheumatoid arthritis 
RT-PCR = reverse transcriptase-polymerase chain reaction 
SEM = standard error of the mean 
SLE = systemic lupus erythematosus 
SMA = smooth muscle actin 
sPGA = static Physician’s Global Assessment 
TGF-β = transforming growth factor-beta 
TLR4 = toll-like receptor 4 
TNF-α = tumor necrosis factor alpha 
VEGF = vascular endothelial growth factor 
1. INTRODUCTION 
cAMP is a pivotal second messenger that regulates inflammatory responses (Taskén K. 
Physiol Rev. 2004 Jan;84(1):137-67. Review. PubMed PMID: 14715913). cAMP is 
degraded through the activity of the large superfamily of phosphodiesterases (PDE) 
(Conti M, Annu Rev Biochem. 2007;76:481-511. Review. PubMed PMID: 17376027). 
Within this group, enzymes of the four-gene PDE4 family play a key role in degrading 
cAMP in inflammatory cells, as well as endothelial cells, smooth muscle cells and 
keratinocytes (Houslay MD. Drug Discov Today. 2005 Nov 15;10(22):1503-19. Review. 
PubMed PMID: 16257373). Encoded by the PDE4A, PDE4B, PDE4C, and PDE4D 
genes, there are also more than 20 splice variants due to differential mRNA splicing  
genes (Manganiello VC, Murata T, Taira M, Belfrage P & Degerman E. Perspectives in 
biochemistry and biophysics: Diversity in cyclic nucleotide phosphodiesterase isozyme 
families. Arch Biochem Biophys 1995; 322: 1–13 PubMed PMID: 7574662). PDE4 
isoforms display a differential expression pattern in human testis, skeletal muscle, lung 
and brain (Obernolte R, Ratzliff J, Baecker PA, Daniels DV, Zuppan P, Jarnagin K, 
Shelton ER. Multiple splice variants of phosphodiesterase PDE4C cloned from human 
lung and testis. Biochim Biophys Acta. 1997 Sep 12;1353(3):287-97. PMID: 9349724; 
Enoksson S, Degerman E, Hagström-Toft E, Large V, Arner P. Various 
phosphodiesterase subtypes mediate the in vivo antilipolytic effect of insulin on adipose 
tissue and skeletal muscle in man. Diabetologia. 1998 May;41(5):560-8. PMID: 
9628274; Pérez-Torres S, Miró X, Palacios JM, Cortés R, Puigdoménech P, Mengod G. 
Phosphodiesterase type 4 isozymes expression in human brain examined by in situ 
hybridization histochemistry and[3H]rolipram binding autoradiography. Comparison with 
monkey and rat brain. J Chem Neuroanat. 2000 Dec;20(3-4):349-74. PMID: 11207431).  
However, the expression patterns of PDE4 isoforms have not been studied in blood or 
skin of patients with inflammatory disease such as psoriasis. 
   PDE4 inhibitors are a well-characterized class of pharmaceutical agents, with a broad 
range of anti-inflammatory activities in vitro, and in in vivo preclinical models of asthma, 
lung neutrophilia, arthritis, inflammatory bowel disease, multiple sclerosis, osteoporosis 
and other conditions (Videla S,. J Pharmacol Exp Ther. 2006 Feb;316(2):940-5. Epub 
2005 Oct 27. PubMed PMID: 16254133; Keshavarzian A, Expert Opin Investig Drugs. 
2007 Sep;16(9):1489-506. Review.PubMed PMID: 17714033; Press NJ Prog Med 
Chem. 2009;47:37-74. Review. PubMed PMID:19328289). Apremilast is a novel, orally 
administered, small molecule phosphodiesterase 4 (PDE4) inhibitor approved for 
treatment of psoriatic arthritis (PsA) and moderate to severe plaque psoriasis 
(Abdulrahim H, Thistleton S, Adebajo AO, Shaw T, Edwards C, Wells A. Apremilast: a 
PDE4 inhibitor for the treatment of psoriatic arthritis. Expert Opin Pharmacother. 2015 
May;16(7):1099-108. doi: 10.1517/14656566.2015.1034107. Epub 2015 Apr 11. 
Review. PMID: 25864487; Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, 
Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb 
AB. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients 
with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, 
controlled trial (ESTEEM 2). Br J Dermatol. 2015 Sep 10. doi: 10.1111/bjd.14164. [Epub 
ahead of print] PMID: 26357944). Apremilast, by inhibiting PDE4, elevates intracellular 
cAMP levels and thus down-regulates the inflammatory response by modulating 
expression of a network of pro-inflammatory and anti-inflammatory mediators implicated 
in psoriasis and PsA (Gooderham M, Papp K. Apremilast in the Treatment of Psoriasis 
and Psoriatic Arthritis. Skin Therapy Lett. 2015 Sep;20(5):1-6. PMID: 26382906). Selige 
et al. found different PDE4 subtypes with distinct functions in human lung fibroblasts 
and highlighted the predominant role of PDE4B in controlling pathophysiological 
processes of human lung fibroblasts. This provides a rationale for targeting of PDE4B to 
treat respiratory diseases with fibrotic lesions in the lung (Selige J, J Cell Physiol. 2010 
May;223(2):317-26. PubMed PMID: 20082309). Schafer et al showed that apremilast, a 
PDE4 inhibitor, does not inhibit proliferation in normal primary human epidermal 
keratinocytes. On the other hand, apremilast inhibited TNF-α production by 
keratinocytes upon UVB treatment (50 mJ/cm2) (Schafer PH, Br J Pharmacol. 2010 
Feb;159(4):842-55. PubMed PMID: 20050849). Sachs et al. found a new mechanism in 
which PDE4A4/5 interacts with CD271 to enhance cAMP degradation. The CD271-
dependent down-regulation of cAMP results in a decrease in extracellular proteolytic 
activity (Sachs BD. J Cell Biol. 2007 Jun 18;177(6):1119-32. PubMed PMID: 17576803). 
CD271 is a neurotrophin (NT) receptor, also known as p75NTR,  which belongs to the 
TNF receptors superfamily and shares with the other members of the family the death 
domain. The role of CD271 is complex: it may increase  high-affinity binding of Trk 
receptors to NTs, and enhances their survival signal. By contrast, CD271 alone can 
induce apoptosis upon specific binding, such as with β-amyloid, via its own transduction 
pathway and by interacting with a mounting number of downstream molecules (Dechant 
G. Nat Neurosci. 2002Nov;5(11):1131-6. Review. PubMed PMID: 12404007). NT and 
their receptors have autocrine and paracrine functions within the skin (Botchkarev VA.J 
Invest Dermatol. 2006 Aug;126(8):1719-27. Review. PubMed PMID: 16845411). 
Moreover, our group has recently demonstrated that CD271 is expressed by basal 
keratinocytes, specially by transit amplifying (TA) cells (Truzzi et al, 2011, 18:948-958 
Cell Death and Diff. PMID: 21151024). It should be noted that the crosstalk between the 
epidermal and dermal compartment is necessary to sustain epidermal homeostasis, and 
that some factors that are produced in the dermal compartment act on stem cells that 
reside in the epidermis. Moreover, Palazzo et al showed that both dermal human 
fibroblasts and myofibroblasts express NT, CD271 and Trk receptors and that NTs exert 
a critical role in tissue remodelling and wound healing (Palazzo E et al 2012. PubMed 
PMID 21503896) 
   In the current set of experiments, we report gene expression patterns of PDE4 
isoforms (A,B,C,D) in peripheral blood mononuclear cells (PBMC) from healthy donors 
and from patients with a variety of immune-mediated or inflammatory diseases including 
psoriasis, as well as the effect of apremilast on cytokine and chemokine production from 
PBMC of patients with psoriasis. We further report immunohistochemistry studies 
showing the isoform distribution of PDE4 in skin samples from healthy donors and 
psoriasis, atopic dermatitis and discoid lupus patients. We then examine PDE4 isoform 
binding to CD271 in fibroblasts cultured from healthy skin, and analyze the function of 
the CD271-PDE4 complex in fibroblasts. 
 
2. MATERIALS AND METHODS 
2.1. Gene Expression Analysis of PDE4 isoforms in PBMC 
 Viably frozen PBMC and autologous serum from healthy volunteers or patients 
with psoriasis, RA, IPF, sarcoidosis, scleroderma, Crohn’s disease, or SLE (n=5 from 
each disease) were purchased from Coversant Healthcare Systems (Huntsville, 
Alabama). The diagnosis of disease was made on a case report form by the responsible 
physician in a network of medical clinics, research clinics, hospitals, and outpatient 
medical facilities. PBMC were thawed and cultured in RPMI-1640 supplemented with 
5% of each patient’s autologous serum for 24 hours to allow cells to recover from 
freezing and thawing. Cells (1x106 PBMC per patient) were collected for gene 
expression analysis by hybridization array. Cells were washed with cold phosphate-
buffered saline, lysed with 350 μL RLT buffer (Qiagen, Gaithersburg, Maryland), and 
transferred to barcoded tubes. RNA was extracted and converted to cDNA using the 
Ovation Whole Blood Solution (NuGEN Technologies, San Carlos, California), and 
hybridized to HG-U133 Plus 2.0 Arrays (Affymetrix, Santa Clara, California). Gene 
expression data were normalized and provided by Covance Genomics Laboratory 
(Seattle, Washington). Statistical comparison for PBMC from each disease versus 
normal control was by one-way ANOVA. 
 
2.2. qRT-PCR  
 Quantitative RT-PCR was performed to confirm overexpression of PDE4B and 
PDE4D isoforms in PBMC from patients with psoriasis. PBMC samples (n=20 each from 
psoriasis patients and healthy donors) were cultured for 24 hours in 5% autologous 
serum. RNA was isolated, converted to cDNA and analyzed by qRT-PCR, and a 
comparison of PBMC from psoriasis patients versus normal controls was conducted by 
t-test. 
 
2.3. Multiplexed Bead-Based Immunoassay 
 PBMCs from psoriasis patients (n=10) were obtained after informed consent by 
Conversant Healthcare Systems (Huntsville, Alabama). The diagnosis of psoriasis was 
made on a case report form by the responsible physician in a network of medical clinics, 
research clinics, hospitals, and outpatient medical facilities. PBMCs were thawed 
(minimum viability was 80%), plated at 2x105 cells/well, and stimulated in duplicate via 
various immune receptors with or without apremilast (1 μM) in 0.1% dimethyl sulfoxide 
for 24 hours. Immune cell stimuli included 1 ng/mL LPS (Sigma), targeting TLR4 on 
monocytes, dendritic cells, and B cells; 10 ng/mL each of staphylococcal enterotoxin A 
and B (Toxin Tech), targeting T-cell receptors; 2 ng/mL each of TNF-α + IL-1β (Sigma), 
targeting TNF and IL-1 receptors on monocytes, dendritic cells, B cells, T cells, and 
natural killer cells; and 2 μg/mL anti-IgM (Jackson IR), targeting B-cell receptors. 
 The production of 25 protein analytes was measured by cytometric bead array 
using Milliplex MAP Human Cytokine/Chemokine beads (EMD Millipore Corporation, 
Billerica, MA) on a MagPix instrument (Luminex, Austin, TX). 
  
2.4. Skin Immunohistochemistry (IHC) 
 Immunohistochemistry was performed on dermis samples from healthy controls 
and from patients with psoriasis, atopic dermatitis (AD), and discoid lupus 
erythematosus (DLE) at University of Modena and Reggio Emilia, Modena, Italy. 
Paraffin embedded biopsies (4µm) were stained for protein analysis by IHC as 
follows: PDE4A, rabbit polyclonal antibody (1:100, Proteintech Group, Chicago, IL, 
USA); PDE4B, rabbit polyclonal antibody (1:40, Santa Cruz Biotechnology, INC, Santa 
Cruz, CA); PDE4C, rabbit polyclonal (1:40, Santa Cruz Biotechnology); PDE4D, rabbit 
polyclonal antibody (1:40, Santa Cruz Biotechnology); CD271, mouse monoclonal 
antibody (1:100, Upstate, Lake Placid, NY, USA). After washes,  slides  were incubated  
with  secondary  antibody  for  45  minutes  at  room  temperature. Fast Red was used 
as cromogen, stainings were performed according to the UltraVision LP Detection 
System AP Polymer & Fast Red Chromogen assay (Thermo Fisher Scientific, 
Waltham, MA, USA). The  expression  intensity  was  quantitatively  determined  using  
ImageJ software  (Wayne  Rasband,  National  Institute  of  Mental  Health,  Bethesda,  
MD,  USA).  Detailed Histopathology and immunohistochemistry of PDE4A, PDE4B, 
and PDE4D protein expression in psoriatic skin was performed by LifeSpan 
Biosciences, Inc. (Seattle, WA) using the primary antibodies as described above. The 
principal detection system consisted of a Vector anti-rabbit secondary (BA-1000) and a 
Vector ABC-AP kit (AK-5000) with a Vector Red substrate kit (SK-5100). 
 
2.5. Isolation of primary fibroblasts and cell treatment  
 Normal human dermal fibroblasts (DF) were isolated from healthy skin biopsies 
obtained from waste materials from Operating Room. Patient consent for experiments 
was not required because Italian laws considers human tissue left over from surgery as 
discarded material. Briefly, DF were obtained by explant culture and grown in 
Dulbecco’s modified Eagle’s medium (DMEM) containing 5% fetal bovine serum (FBS). 
Transforming growth factor- β1 (TGF-β1) (1 ng/mL, Sigma, St. Louis, Missouri) was 
added in fibroblast secondary culture for six days to promote differentiation into 
myofibroblasts (DM). The myofibroblast phenotype was checked by immunostaining in 
situ of α-smooth muscle actin (α-SMA). 
For cell treatment, Apremilast was diluited in DMSO 10mM and used at the final 
concentration of 10μM in culture medium without serum. DF and MF were plated in 
DMEM with FBS. 48h after seeding, Apremilast or DMSO were added to DMEM for 2 
hours and, after that, diluent, 100 ng/ml human recombinant NGF (Sigma–Aldrich), 
1ng/ml TGF‐β1 (Sigma-Aldrich), 40μM β-amyloid 25-35 (Bachem, Bubendorf, 
Switzerland) were added to medium. Cells were monitored and used for further 
experiments 48 hours later. 
 
2.6. Immunofluorescence (IF) in situ 
DF were plated on chamber slides and, 48 hours after seeding, were treated with TGF-
β1 (1 ng/mL, Sigma-Aldrich, St. Louis, MO, USA) or diluent alone. Six days later, cells 
were fixed in situ in 4% paraformaldehyde for 20 min and air dried. After a rehydration in 
PBS, cells were permeabilized for 10 min with 0.5% Tryton X-100 in 0.1% sodium 
citrate, treated for 5 min with 50 mM NH4Cl and incubated with 1% bovine albumin 
serum for 20 min. Then slides were incubated for 1 hour at room temperature with the 
mouse monoclonal anti-α-SMA antibody (1:400, Sigma-Aldrich). Then cells were 
incubated with secondary antibody, Alexa Fluor 488 (1:100, Thermo Fisher Waltham, 
MA, USA). Finally, cell nuclei were stained with 1μg/ml Dapi (Sigma-Aldrich). 
Micrographs were taken on a Confocal Scanning Laser Microscopy (Leica TCS SP2) 
(Leica, Exton, PA, USA). 
 
2.7. Co-Immunoprecipitation 
 DF and DM were cultured until pre-confluent condition. Cells were harvested with 
lysis buffer pH 7.5 (150 nM NaCl, 15 mM MgCl, 1 mM EGTA, 50 mM Hepes, 10% 
glycerol, 1% Triton) containing protease inhibitors. Monoclonal antibody CD271 
(Upstate, Lake Placid, New York), was bound to sepharose beads for 1 h at 4 ºC under 
rotation. Thereafter, pre-cleared lysates were conjugated to sepharose beads-antibody 
complex or, as control, to sepharose beads alone or to antibody alone, overnight at 4 ºC 
under rotation. Immunocomplexes were washed with binding buffer (50 mM Tris-HCl, 
pH 7.5; 100 mM NaCl; 2 mM MgCl2, 1 mM DTT, 0.5% Triton X-100, 0.5% bovine serum 
albumin) six times. Samples were eluted with 2x Laemnli sample buffer for 5 minutes at 
90 ºC and Western blotting for PDE4A, B, C and D was performed as described below. 
 
2.8. Western Blotting 
 Total proteins (20 μg) or immunocomplexes were analyzed under non-reducing 
conditions on 7.5% polyacrylamide gels. To obtaine total proteins, cells were washed 
with phosphate-buffered saline (PBS) and lysed on ice, in lysis buffer pH 7.5 (150 nM 
NaCl, 15 mM MgCl, 1 mM EGTA, 50 mM Hepes, 10% glycerol, 1% Triton) containing 
protease inhibitors. Briefly, after the electrophoretic separation, total proteins or 
immunocomplexes were blotted onto nitrocellulose membranes. The blots were blocked 
for 2 hours in blocking buffer (PBS buffer, pH 7.4 with 0.2% Tween 20 and 5% nonfat 
milk) and incubated with rabbit polyclonal anti-human PDE4A antibody (1:1000, 
Proteintech group), rabbit polyclonal anti-human PDE4B antibody (1:300, Santa Cruz 
Biotechnology), rabbit polyclonal anti-human PDE4C antibody (1:300, Santa Cruz 
Biotechnology), rabbit polyclonal anti-human PDE4D antibody (1:300, Santa Cruz 
Biotechnology) or mouse monoclonal a-SMA (1:3000, Sigma-Aldrich) or mouse 
monoclonal anti-β-actin (1:1000; Sigma)  overnight at 4 ºC. Then membranes were 
washed in TBS/Tween 20, incubated with peroxidase-conjugated goat anti-mouse or 
goat anti-rabbit or anti-mouse (1:3000, Biorad, Hercules, CA) antibodies for 45 min at 
room temperature. Finally, membranes were washed and developed using the ECL 
chemiluminescent detection system (Amersham Biosciences UK Limited, Little Chalfont 
Buckinghamshire, England). The band intensity was quantitatively determined using 
ImageJ software (Wayne Rasband, National Institute of Mental Health, Bethesda, MD, 
USA), and protein levels’ intensity was normalized to β-actin expression. 
 
2.9 MTT Assay  
DF and DM were plated in a 96-well tissue culture plate (5000 cells/well). 48 hours after 
plating, cells were treated as described above with apremilast or DMSO for 2 hours, 
then treated with diluent (control), NGF (100 ng/mL), NT3 (100 ng/mL), or β-amyloid (40 
μM). MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was 
performed 48 hours later. Proliferative cells were detected by incubating with MTT 
(Sigma-Aldrich) solution at 37 ºC for 4 hours. The formazan dye produced after DMSO 
solubilization was evaluated by a multiwall scanning spectrophotometer at 540 nm. The 
results are expressed as viability percentage, as compared to control. Results are 
calculated as the mean ± SD of three different experiments. Student’s t-test was 
performed for comparison of the means.  
 
2.10. Propidium Iodide (PI) staining 
At 48 hours after cell seeding, DF and DM were pretreated with DMSO or apremilast as 
described above, then diluent (control) or 40 µM β-amyloid were added. After 48 hours, 
cells were trypsinized and resuspended (5x105 cells) in 1 mL hypotonic fluorochrome 
solution: 50 mg/mL PI containing 0.1% sodium citrate and 0.5% TrytonX-100 (Sigma). 
After 15 minutes, cells were analyzed using an Epics XL flow cytometer (Coulter 
Electornics Inc., Hialeah, FL). Apoptosis was detected by evaluating the fluorescence of 
hypodiploid cells counted in subG1 region. 
 
2.11. TUNEL Assay 
DF and DM after treatment were fixed in situ in paraformaldehyde (4% in PBS) and air-
dried. The slides were stained with the “In situ cell death detection kit” (Roche 
Diagnostics, Basel, Switzerland) as recommended by the manufacturer. Fluorescent 
specimens were analyzed by confocal scanning laser microscopy (Leica TCS SP2, 
Leica microsystems, Wetzlar, Germany) in conjunction with a conventional optical 
microscope (Leica DM IRBE, Leica). Results are calculated as the mean ± SD of three 
different experiments. 
 
2.12. Migration Assay  
 A total of 20x104 DF were plated on 12-well tissue culture plates. 48 hours after 
seeding, cells were pretreated with DMSO or apremilast for 2 hours as described 
above, then cells were treated with 5 mg/mL mitomycin C for 1 hr 30 min. Subsequently, 
the cells were washed three times in serum-free medium and a line for each well was 
drawn along the cell monolayer with a sterile plastic tip. Plates were washed twice with 
serum-free medium to remove all detached cells and incubated in medium with BSA 
0.1% with 1 ng/mL TGF-β1, 100 ng/mL human recombinant NGF in presence of DMSO 
or apremilast. Cells were monitored at 24 and 48 hours from stimulation. The result of 
each experiment was expressed as the mean of migrated cells from three different 
areas. The final results are expressed as the mean ± SD of three different experiments. 
 
2.13. cAMP ELISA 
 At 48 hours after cell seeding, DF and DM were pretreated with DMSO or 
apremilast as described above, then diluent, 100 ng/mL human recombinant NGF 
(Sigma-Aldrich), or 40 μM β-amyloid (Bachem) were added to the culture medium.  
48 hours later, supernatants were collected, particulates were removed by 
centrifugation and stored at -20 ºC. cAMP quantitation was performed by a competitive 
enzyme immunoassay (R&D Systems cAMP immunoassay, R&D Systems, 
Minneapolis, MN) according to manufacturer instructions. The sample concentration 
was determined by absorbance at 540 nm against a standard curve. cAMP levels are 
given in pmol/mL of cell lysate and results are expressed as mean ± SEM of triplicate 
from three different experiments. 
 
3. RESULTS 
3.1. Gene expression analysis of PDE4 isoforms in PBMC 
 We first wanted to analyze gene expression of PDE4 isoforms (A, B, C, and D) 
in PBMC from healthy donors and from patients with 7 different immune-mediated or 
inflammatory diseases: psoriasis, rheumatoid arthritis (RA), idiopathic pulmonary 
fibrosis (IPF), sarcoidosis, scleroderma, Crohn’s disease, and systemic lupus 
erythematosus (SLE). PDE4B and PDE4D isoforms were increased at the mRNA level 
in PBMC from psoriasis patients relative to normal controls (Figure B and D, p<0.05). 
PDE4D was also increased versus normal controls in PBMC from patients with SLE 
(Figure 1D, p<0.05). PDE4C mRNA was preferentially overexpressed in PBMC from 
patients with Crohn’s disease versus normal controls (Figure 1C), while PDE4A mRNA 
expression levels were similar across PBMC from normal controls and patients with the 
various immune/inflammatory diseases (Figure 1A). To confirm the overexpression of 
PDE4B and PDE4D mRNA in PBMC from patients with psoriasis relative to normal 
controls, quantitative RT-PCR  was performed using 20 samples each from psoriasis 
patients and healthy donors. Mean relative gene expression in PBMC from psoriasis 
patients was 5.4-fold higher for PDE4B, and 2.2-fold higher for PDE4D (p<0.0001 for 
both vs normal control), compared with 1.1-fold for PDE4A (p=NS) (Figure 1E). There 
were no significant correlations between PDE4A, PDE4B, or PDE4D gene expression in 
the psoriatic PBMC with PASI, BSA, or sPGA scores (data not shown). 
   
 
3.2. Effect of apremilast on the production of inflammatory mediators by PBMC 
from patients with psoriasis 
 Given the high PDE4 expression in psoriasis, we investigated the effect of 
apremilast on cytokines produced by PBMC from psoriatic patients. Psoriasis patient 
PBMC donors (n=10) included 5 females and 5 males ranging in age from 26 to 42 
years, with PASI scores ≤26 and ≤33% body surface area affected. Two patients also 
had a diagnosis of psoriatic arthritis. Changes in production of various cytokines and 
chemokines upon stimulation of PBMCs from these psoriasis patients with LPS, 
staphylococcal enterotoxin A and B, TNF-α/IL-1β, or anti-IgM are shown in Figure 2A. 
Addition of 1 μM apremilast had the greatest effect on psoriatic PBMC cultures 
stimulated via TLR4 (ie, LPS stimulation), with 13 of the 25 analytes significantly 
affected versus LPS control (Figure 2B). Specifically, apremilast caused significant 
inhibition of LPS-induced TNF-α, IL-12/IL-23p40, IFN-γ, IP-10, MCP-1, MCP-3, MIP-1β, 
IL-1α, IL-1β, and GM-CSF production, and increased IL-10, G-CSF, and VEGF 
production. In psoriatic PBMC stimulated with anti-IgM to ligate the B cell receptor, 
apremilast decreased production of the cytokines TNF-α, IL-1α, and IFN-γ, and the 
chemokines MCP-1, MCP-3, MIP-1β, and IP-10, and increased IL-10, G-CSF, VEGF, 
and IL-6. In psoriatic PBMC cultures stimulated via the T-cell receptor or TNF and IL-1 
receptor, apremilast had far fewer effects (data not shown). 
   
3.3. PDE4 expression in inflammatory skin infiltrates 
 Psoriasis is an immune-mediated disease characterized by a dense dermal 
infiltrate extravasating from the blood stream. Immuno-inflammatory infiltrate in turn is 
responsible for the epidermal alterations. For this reason, we focused on the expression 
of PDE4 proteins, that are markedly elevated in PBMC from psoriatic patients, in the 
dermal infiltrate from lesional psoriatic skin. Also dermis from healthy subjects, atopic 
dermatitis (AD), and discoid lupus erythematosus (DLE) was evaluated. In general, 
PDE4 staining was higher in diseased vs. normal skin when measured by ImageJ 
software (Figure 3B). PDE4A was expressed at the cytoplasmic level in a few dermal 
cells, most likely fibroblasts, in healthy skin, while it was markedly increased in 
fibroblasts from psoriasis, AD, and discoid lupus  erythematous (DLE). PDE4B was 
slightly expressed by dermal cells both in healthy and psoriatic skin. In AD, PDE4B  
staining was somewhat more expressed in the dermis of AD skin as compared to 
controls. In this context, dermal fibroblasts appeared intensely positive. In dermis from 
DLE skin, PDE4B staining was markedly increased, as compared to healthy controls, 
dermal fibroblasts being strongly positive. PDE4C was considerably more expressed in 
the dermis from psoriatic or AD sections than in skin from healthy controls. In DLE, 
PDE4C staining intensity was higher than in AD or psoriasis, fibroblasts being intensely 
stained. PDE4D expression was markedly higher in dermal infiltrate (fibroblasts) from 
psoriasis, AD or DLE than in healthy skin. Finally, CD271 appeared more expressed in 
fibroblasts from psoriasis and AD than in healthy skin or DLE (Figure 3A).  
   In order to better characterize PDE4 protein expression in psoriatic skin, a more 
detailed analysis was performed in the dermis. PDE4A, B, and D staining was evaluated 
and interpreted by a pathologist, and each antibody was evaluated for the presence of 
specific signal and level of background. Staining intensity was recorded on a 0–4 scale 
(0=negative, 1=blush, 2=faint, 3=moderate, 4=strong) (Table 1). Overall, lymphocytes 
present in the psoriatic skin were moderately to strongly positive for PDE4A and 
PDE4B, and faintly positive for PDE4D. Pilosebaceous units, sweat glands, sweat 
ducts, hair follicles, and arrector pili smooth muscle were positive. Fibroblasts were 
positive, and endothelium stained strongly for PDE4A, PDE4B, and PDE4D. 
Specifically, PDE4A expression showed increased intensity and prevalence of staining 
in nearly all cell types in psoriatic vs. normal samples, although neutrophils within 
microabscesses were exceptionally negative. PDE4B staining in psoriatic samples was 
very prominent in vessels in the superficial dermis, and positively stained inflammatory 
cells were more abundant than in normal samples. PDE4D staining in psoriatic samples 
was present in fibroblasts and endothelium. Lymphocytes showed frequent staining in 
both normal and psoriatic skin samples, but were far more prevalent in the psoriasis 
samples. The endothelium of psoriatic skin showed a relatively large increase in PDE4 
expression compared to normal skin, with PDE4A and PDE4D displaying strong 
staining in psoriatic endothelium, but only faint staining in normal endothelium. In 
fibroblasts, PDE4A expression was moderate to strong in psoriatic skin, but absent in 
normal skin. PDE4D expression was moderate in psoriatic fibroblasts, but faint in 
normal fibroblasts. In overall terms of staining intensity, the endothelium and fibroblasts 
showed the largest consistent increase in PDE4 expression in psoriatic vs. normal skin. 
 
3.4. PDE4 isoforms co-immunoprecipitate with CD271 in fibroblasts  
 Due to the large increase in PDE4 staining observed in psoriatic fibroblasts, this 
cell type was selected for functional studies to determine the role of PDE4 in cellular 
responses. Different proinflammatory cytokines, including TGF-b1, promote fibroblast 
differentiation into myofibroblasts, characterized by the expression of a-Smooth Muscle 
Actin (a-SMA). These cells are predominantly responsible for connective-tissue 
contracture and ECM reorganization in different physiopathologic processes in the skin, 
including wound healing and fibrosis (Verjee et al 2013/ PMID:23431165). We showed 
that all PDE4 isoforms are expressed in dermal fibroblasts (DF) and myofibroblasts 
(DM) cultured from healthy donors at the mRNA level (Figure 4A, B, C), while PDE4 
protein levels are higher in DM than in DF (Figure 4D). PDE4A had previously been 
found to associate with the CD271 to enhance cAMP degradation in fibroblasts, and to 
regulate fibrotic responses [Sachs BD, Baillie GS, McCall JR, et al. J Cell Biol. 2007 Jun 
18;177(6):1119-32. PubMed PMID: 17576803]. Because CD271 is also expressed in 
skin fibroblasts (Palazzo et al, 2012, J Cell Physiol), we wanted to determine if PDE4 
isoforms (PDE4A,B,C, and D) co-localize with CD271 in dermal fibroblasts. We showed 
that PDE4 isoforms co-immunoprecipitate with CD271 in DM (Figure 4E). However, in 
DF, CD271 formed only weak complexes with PDE4A and PDE4B and no complex with 
PDE4C or PDE4D.   
  
3.5. PDE4-CD271 complex function in fibroblasts in vitro 
 To evaluate the effect of the PDE4-CD271 complex on proliferation and 
apoptosis in fibroblasts, DF and DM were pretreated with apremilast or DMSO for 2 
hours and then treated with NGF, NT3, β-amyloid, or diluent. Treatment with β-amyloid 
significantly decreased the percentage of proliferative cells for both DF and DM cultures 
compared with diluent control. In DM, the addition of apremilast significantly inhibited 
the effect of β-amyloid (p<0.05 vs DMSO), while apremilast had no effect versus DMSO 
in DF (Figure 5A, B). Similarly, the addition of apremilast significantly reduced the 
induction of apoptosis by β-amyloid treatment in DM (p<0.05 vs DMSO, Figures 5D, F) 
but not in DF (Figures 5C E). 
 It has been shown previously that neurotrophins mediate DF migration, and that 
neurotrophins as well as TGF-β1 induce DF to differentiate into DM by expressing α-
SMA.{Palazzo, 2012 3572 /id} We therefore analyzed whether the addition of apremilast 
could affect DF migration and α-SMA expression. Apremilast inhibited DF migration 
induced by both NGF and TGF-β1 treatment (Figure 6A, B). Similarly, apremilast 
inhibited the up-regulation of α-SMA expression induced by NGF and TGF-β1, 
especially 6 days after treatment (Figure 6C).  
 cAMP ELISA was performed to evaluate if activation of the CD271-PDE4 
complex leads to cAMP degradation. In this analysis, neither apremilast alone nor 
apremilast in combination with NGF exerted any significant effect on release of cAMP 
by either DF or DM (Figure 7A). On the other hand, in DM, Apremilast reduced cAMP 
degradation induced by treatment with β-amyloid (Figure 7B) 
 
4. DISCUSSION 
 In this series of experiments characterizing the role of PDE4 isoforms in 
psoriasis, gene expression studies indicate that PDE4B and PDE4D mRNA are 
overexpressed in PBMC from donor patients with psoriasis relative to normal controls 
(healthy volunteers) or patients with other inflammatory and immune-mediated 
diseases. PCR experiments confirmed that, on average, the overexpression of the 
PDE4B gene is 5.4-fold, and the overexpression of the PDE4D gene is 2.2-fold, 
compared with normal PBMC. Regarding the effect of the PDE4 inhibitor apremilast on 
cytokine/chemokine production of stimulated PBMCs from patients with psoriasis, 
apremilast has the greatest effect on responses to TLR4 receptor stimulation, with a 
similar pattern observed in B cell receptor-stimulated PBMC. Apremilast consistently 
decreases production of the cytokines TNF-α, IL-1α, and IFN-γ, and the chemokines 
MCP-1, MCP-3, MIP-1β, and IP-10. In psoriatic PBMC cultures stimulated via the T-cell 
receptor or TNF and IL-1 receptors, apremilast has far fewer effects. On the other hand, 
apremilast induces an up-regulation of IL-10 and G-CSF production under all conditions. 
   Because of the higher PDE4 gene expression observed in psoriasis patient blood, a 
careful analysis of the skin was conducted. PDE4 protein expression is higher in the 
skin of patients psoriasis, atopic dermatitis, and discoid lupus, as compared to normal 
skin. In a detailed IHC analysis of PDE4 protein expression in psoriatic skin, the 
endothelium and fibroblasts, in particular, shows increased expression of PDE4A and 
PDE4D, as compared to normal skin. Little had previously been known about the 
expression of PDE4 isoforms in human dermal fibroblasts.  Selige and co---workers  
showed that primary normal human lung fibroblasts  (NHLF) express PDE4A, B, 
and D, while PDE4C is only barely detected (Selige J, J Cell Physiol.2011, 
226:1970-80.). In the present study, we found that all PDE4 isoforms are expressed 
in both DF and DM, even if at different levels. Regarding dermal compartment, all 
PDE4 isoforms are expressed at the mRNA level both in DF and DM. DM express 
higher level of PDE4 isoform proteins than DF. DM invade and repair injured tissues 
by secreting and organizing the extracellular matrix and by developing contractile 
forces. At the end of the normal  repair  process,  DM disappear  by apoptosis.  In 
pathologic conditions, DM likely remain,  leading  to excessive  scarring (Micallef L, 
Vedrenne N, Billet F, Coulomb B, Darby IA, Desmoulière A. The myofibroblast, 
multiple origins for major roles in normal and pathological tissue repair. Fibrogenesis 
Tissue Repair. 2012,  5 Suppl 1:S5.). Indeed, DM  play  an  important  role  in  
organogenesis,  oncogenesis, inflammation,  repair, and fibrosis in most organs and 
tissues (Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. 
Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol. 1999, 
277:C1---9.). We found that all four PDE4 proteins are up-regulated in cells of the 
dermal compartment in biopsies from inflammatory conditions. We postulate that 
these cells could be DM, and suggest that PDE4 proteins play a role in the above 
mentioned DM functions, although more functional studies are definitely needed. 	
 Because PDE4 isoforms are expressed in dermal fibroblasts and evidence has 
indicated an interaction between PDE4 and the CD271, which may be important in 
tissue remodeling and wound healing,{Palazzo, 2012 3572 /id}, we assessed the effect 
of PDE4 inhibition on the function of the PDE4-CD271 complex in DF and DM. We first 
showed all PDE4 isoforms co-immunoprecipitate with CD271 in DM. Inhibition of PDE4 
with apremilast reduces cAMP degradation mediated by β-amyloid in DM, as well as β-
amyloid-mediated induction of apoptosis and reduction of proliferative cells . Addition of 
apremilast also reduces DF migration and differentiation mediated by NGF and TGF-β1. 
Taken together, these results indicate that PDE4 play an important role in psoriasis. In 
addition, the study reveals that the complex PDE4/CD271 could be important in 
modulating fibroblasts functions. 
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Table 1. Detailed Summary of PDE4 IHC Staining Scores in Normal and Psoriatic Skin 
Skin sections were stained with antibodies specific for PDE4A, B, C, or D and 
interpreted by a pathologist. Each antibody was evaluated for the presence of specific 
signal and level of background. Staining intensity was recorded on a 0–4 scale 
(0=negative, 1=blush, 2=faint, 3=moderate, 4=strong). Data shown are the mean values 
determined by staining of skin sections from 3 normal subjects and 3 psoriatic patients.  
 
PDE4 Isozyme  
Normal Psoriatic 
A B C D A B C D 
Squamous epithelium 4.0 NR  1.0 2.2 4.0 1.5 1.5 2.8 
Arrector pili smooth muscle 3.3 2.0 2.0 2.5 NR  2.0 2.0 2.3 
Sweat glands/ducts 3.3 2.0 2.0 2.3 4.0 2.0 2.5 2.5 
Pilosebaceous units 2.8 2.0 2.0 2.0 4.0 2.0 2.5 NR  
Vascular smooth muscle 2.5 2.0 2.0 2.0 4.0 2.0 2.0 NR  
Endothelium  2.0 2.0 2.0 2.3 4.0 3.2 3.0 4.0 
Inflammatory cells 2.5 3.0 2.0 2.5 4.0 2.5 2.5 2.3 
Peripheral nerves 1.3 0.0 1.0 1.0 2.3 0.0 1.5 2.0 
Adipocytes  0.5 0.5 0.3 1.3 0.0 0.0 0.3 0.0 
Fibroblasts  0.0 1.0 1.0 2.0 3.5 1.0 1.9 3.0 
FIGURE LEGENDS 
 
Figure 1. Gene expression analysis of PDE4 isoforms in PBMC from healthy volunteers 
or patients with psoriasis, RA, IPF, sarcoidosis, scleroderma, Crohn’s disease, or SLE. 
(A, B, C, D) PBMC samples (n=5 from each immune/inflammatory condition) were 
cultured 24 hours in 5% autologous serum. RNA was isolated, converted to cDNA and 
hybridized to Affymetrix HG-U133 Plus 2.0 Arrays. Representative results from one 
hybridization probe per gene are shown. *p<0.05 vs normal controls by one-way 
ANOVA. (E) PBMC samples from healthy donors and psoriasis patients (N=20 each) 
were cultured for 24 hours in 5% autologous serum. RNA was isolated, converted to 
cDNA and analyzed by qRT-PCR. Dots represent individual data points. The box 
extends from the 25th to the 75th percentile, the whiskers represent the minimum and 
maximum, and the line in the middle of the box represents the median. (p<0.0001 vs 
normal controls, by t-test). 
 
Figure 2. Modulation of production of inflammatory cytokines and chemokines in 
psoriatic PBMCs. (A) Production of 25 inflammatory cytokines and chemokines by 
psoriatic PBMCs. Data are the absolute mean ± SEM of 10 samples, each tested in 
duplicate, measured by cytometric bead array using Milliplex MAP Human 
Cytokine/Chemokine beads (EMD Millipore Corporation, Billerica, MA) on a MagPix 
instrument (Luminex, Austin, TX). (B) Effect of apremilast on LPS-stimulated PBMCs 
from patients with psoriasis. Data are the mean ± SEM percent relative to LPS control, 
from 10 psoriatic PBMC samples, each tested in duplicate. *p<0.05, **p<0.01, 
***p<0.001 vs LPS control by 2-way ANOVA, followed by Bonferroni post-test to 
compare replicate means. 
 Figure 3. PDE4/CD271 expression in healthy and pathologic dermis. (A) PDE4A, 
PDE4B, PDE4C, PDE4D isoforms and CD271 in dermis from healthy controls and 
patients with psoriasis, atopic dermatitis (AD), and discoid lupus erythematosus (DLE) 
were detected by immunohistochemistry. Fast red was used as cromogen. Bar = 200 
μm (B) The  expression  intensity of PDE4A, PDE4B, PDE4C, PDE4D isoforms and 
CD271 in (A) was quantitatively measured  using  ImageJ software  as described in the 
Materials and Methods. Relative staining intensities are shown, normalized to healthy 
dermis for each individual antibody. 
 
Figure 4. PDE4/CD271 expression in fibroblasts and myofibroblasts in vitro (A) α-SMA 
expression in dermal fibroblasts (DF) and myofibroblasts (DM) obtained after treatment 
with diluent (control) or TGF-β1 (1 ng/mL) for 6 days by immunofluorescence in situ. Cell 
nuclei were counterstained with DAPI (blue); bar = 20 µm. (B) After diluent (control) or 
TGF-β1 treatment, levels of α-SMA were determined by Western blotting analysis. 
Vinculin was used as a loading control. (C) Levels of PDE4A, PDE4B, PDE4C, and 
PDE4D mRNA in DF and DM were determined by RT-PCR analysis. Bar graphs show 
the average densitometry values normalized to β-actin. (D) PDE4 isoform expression in 
DF and DM was determined by Western blot analysis. β-actin was used as a loading 
control. Bar graphs show the average densitometry values normalized to β-actin (fold-
expression). (E) DF and DM protein extracts were immunoprecipitated with CCD271 
antibody and immunoblotted with PDE4A, PDE4B, PDE4C, and PDE4D antibodies and 
with PAS-only as control. 
 
Figure 5. Apremilast modulation of apoptosis in DF or DM. Fibroblast (DF) or 
myofibroblast (DM) cultures were pretreated with apremilast (10 μM) or DMSO for 2 
hours, then NGF (100 ng/mL), NT3 (100 ng/mL), and β-amyloid (40 μM) were added. 
MTT assay was performed 48 hours after stimulation of DF (A) or DM (B). Results are 
represented as percentage with respect to diluent. 48 hours after the addition of stimuli, 
propidium iodide (PI) staining was performed and subG1 peak of DF (C) or DM (D) was 
analyzed for FACS analysis. TUNEL assay was performed and apoptotic nuclei of DF 
(E) and DM (F) were counted. Data represent the mean ± SE of triplicate 
determinations. 
 Figure 6. Effect of apremilast on DF migration and differentiation. DF were pretreated 
with apremilast (10 μM) or DMSO for 2 hours. After that, scratching assay was 
performed and diluent, NGF or TGF-β1 were added to medium as described in Materials 
and Methods. Cell pictures were taken 48 hours later (A) and migrating cells were 
counted (B). (C) DF were pretreated with apremilast or DMSO for 2 hours, after which 
diluent, NGF or beta-amyloid were added to medium. Western blotting was performed 
for α-SMA and β-actin was used as internal control. Bars show the densitometric 
analysis of α-SMA normalized to β-actin. Data represent the mean ± SE of triplicate 
determinations.   
 Figure 7. cAMP degradation by PDE4/CD271 complex activation in DF and DM. DF 
and DM were pretreated with apremilast (10 μM) or DMSO for 2 hours, then NGF or 
beta-amyloid were added to medium as described in Materials and Methods. 
Supernatants of DF (A) or DM (B) were collected 48 hours later and cAMP levels were 
evaluated by ELISA analysis. Data represent the mean ± SE of triplicate determinations.
 
